{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:05:46Z","timestamp":1780585546080,"version":"3.54.1"},"reference-count":134,"publisher":"The Endocrine Society","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Crinetics Pharmaceuticals, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Persistent disease after surgery for acromegaly is common. Expanding medical management options improves long-term biochemical and clinical outcomes, but controversies in acromegaly care remain. We review literature and provide recommendations regarding accelerating diagnosis, biochemical monitoring, symptom variability, preconception\/pregnancy management, predictors of treatment response, and alternative dosing regimens. Delayed diagnosis of acromegaly persists, associated with increased morbidity. Advances in artificial intelligence may reduce diagnostic delay; but ethics, privacy issues, and application in diverse populations present challenges. Symptom variability is observed in patients receiving long-acting somatostatin receptor ligands (SRLs) and with other regimens, even when biochemical control is achieved. Dose titration intervals vary across therapies; discordance between biochemical and clinical response requires consideration of signs and symptoms in addition to insulin-like growth factor 1 levels. Premenopausal women with uncontrolled acromegaly are at risk of increased complications during pregnancy. Data on fertility, pregnancy, and fetal effects of acromegaly drugs are limited to case reports and series. Pregnancies and spontaneous conceptions occur in patients with acromegaly, typically with good maternal and fetal outcomes. Predictive algorithms identifying for whom first-line SRLs will be effective have been validated in investigational contexts, but implementation strategy, accuracy, and standardization in clinic practice are yet undetermined. Finally, alternative dosing regimens show promise for decreasing medication burden, cost, and\/or improving control. We conclude that while there has been progress in emerging medical treatment options, controversies in acromegaly care persist, particularly with regard to patient-centered outcomes and utility of personalized approaches in real-life, large-scale clinical practice.<\/jats:p>","DOI":"10.1210\/clinem\/dgag156","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T11:34:56Z","timestamp":1775993696000},"page":"S107-S122","source":"Crossref","is-referenced-by-count":0,"title":["Current controversies in acromegaly care"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0467-2173","authenticated-orcid":false,"given":"Joanna L","family":"Spencer-Segal","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes and Michigan Neuroscience Institute, University of Michigan , Ann Arbor, MI 48109 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5708-5231","authenticated-orcid":false,"given":"Lisa B","family":"Nachtigall","sequence":"additional","affiliation":[{"name":"Neuroendocrine and Pituitary Tumor Clinical Center, Massachusetts General Hospital , Boston, MA 02114 ,","place":["USA"]},{"name":"Harvard Medical School , Boston, MA 02115 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"21","key":"2026060410081236000_dgag156-B1","first-page":"1106","article-title":"Acromegaly: a review of 100 cases","volume":"87","author":"Gordon","year":"1962","journal-title":"Can Med Assoc J"},{"issue":"4","key":"2026060410081236000_dgag156-B2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1365-2265.1987.tb00805.x","article-title":"Acromegaly","volume":"26","author":"Nabarro","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026060410081236000_dgag156-B3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2265.1980.tb03135.x","article-title":"Epidemiology of acromegaly in the Newcastle region","volume":"12","author":"Alexander","year":"1980","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2026060410081236000_dgag156-B4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.0954-6820.1988.tb15881.x","article-title":"Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984","volume":"223","author":"Bengtsson","year":"1988","journal-title":"Acta Med Scand"},{"issue":"6","key":"2026060410081236000_dgag156-B5","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1210\/jc.2007-2149","article-title":"Changing patterns in diagnosis and therapy of acromegaly over two decades","volume":"93","author":"Nachtigall","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060410081236000_dgag156-B6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1365-2265.2009.03626.x","article-title":"Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed","volume":"72","author":"Reid","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2026060410081236000_dgag156-B7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1530\/ERC-17-0253","article-title":"Acromegaly at diagnosis in 3173 patients from the Li\u00e8ge acromegaly survey (LAS) database","volume":"24","author":"Petrossians","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2026060410081236000_dgag156-B8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1530\/EJE-20-0019","article-title":"Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality","volume":"182","author":"Esposito","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026060410081236000_dgag156-B9","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-097804","article-title":"Estimating diagnostic delay in patients with pituitary adenomas in Sweden: a cross-sectional study","volume":"15","author":"Forsgren","year":"2025","journal-title":"BMJ Open"},{"issue":"1","key":"2026060410081236000_dgag156-B10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12958-023-01057-x","article-title":"Polycystic ovary syndrome preceding the diagnosis of acromegaly: a retrospective study in 97 reproductive-aged women","volume":"21","author":"Khiyami","year":"2023","journal-title":"Reprod Biol Endocrinol"},{"issue":"1","key":"2026060410081236000_dgag156-B11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1210\/jcem-64-1-51","article-title":"Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations","volume":"64","author":"Ho","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026060410081236000_dgag156-B12","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/BF03345496","article-title":"Gender- and age-related differences in the endocrine parameters of acromegaly","volume":"25","author":"Colao","year":"2002","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2026060410081236000_dgag156-B13","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0015-0282(00)01691-5","article-title":"The insulin-like growth factor-I system and hormone replacement therapy","volume":"75","author":"Cardim","year":"2001","journal-title":"Fertil Steril"},{"issue":"2","key":"2026060410081236000_dgag156-B14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/jcem-72-2-374","article-title":"Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women","volume":"72","author":"Weissberger","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2026060410081236000_dgag156-B15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103513","article-title":"Tackling healthcare providers bias: a systematic review of interventions with implications for inclusive clinical research","volume":"89","author":"Grammoustianou","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"19","key":"2026060410081236000_dgag156-B16","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMra2409076","article-title":"Acromegaly","volume":"393","author":"Giustina","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"2026060410081236000_dgag156-B17","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40618-024-02519-8","article-title":"Diagnostic delay, older age, and hormonal levels at diagnosis affect disease burden and mortality in acromegaly","volume":"48","author":"Gasco","year":"2025","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2026060410081236000_dgag156-B18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11102-011-0302-7","article-title":"Screening for acromegaly by application of a simple questionnaire evaluating the enlargement of extremities in adult patients seen at primary health care units","volume":"15","author":"Rosario","year":"2012","journal-title":"Pituitary"},{"issue":"3","key":"2026060410081236000_dgag156-B19","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/cen.12959","article-title":"ACROSCORE: a new and simple tool for the diagnosis of acromegaly, a rare and underdiagnosed disease","volume":"84","author":"Prencipe","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2026060410081236000_dgag156-B20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4158\/EP161575.OR","article-title":"An approach to using data mining to support early identification of acromegaly","volume":"23","author":"Broder","year":"2017","journal-title":"Endocr Pract"},{"issue":"3","key":"2026060410081236000_dgag156-B21","doi-asserted-by":"crossref","first-page":"e892","DOI":"10.1210\/clinem\/dgaf477","article-title":"Facial analysis in acromegaly using machine learning: towards earlier diagnosis","volume":"111","author":"Kocaman","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060410081236000_dgag156-B22","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11102-025-01515-2","article-title":"Acromegaly facial changes analysis using last generation artificial intelligence methodology: the AcroFace system","volume":"28","author":"Rashwan","year":"2025","journal-title":"Pituitary"},{"issue":"1","key":"2026060410081236000_dgag156-B23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/ejendo\/lvad005","article-title":"Real-time detection of acromegaly from facial images with artificial intelligence","volume":"188","author":"Kizilgul","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"2026060410081236000_dgag156-B24","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3389\/fendo.2020.00492","article-title":"Identifying facial features and predicting patients of acromegaly using three-dimensional imaging techniques and machine learning","volume":"11","author":"Meng","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2026060410081236000_dgag156-B25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1159\/000502211","article-title":"Deep-learning approach to automatic identification of facial anomalies in endocrine disorders","volume":"110","author":"Wei","year":"2020","journal-title":"Neuroendocrinology"},{"key":"2026060410081236000_dgag156-B26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ebiom.2017.12.015","article-title":"Automatic detection of acromegaly from facial photographs using machine learning methods","volume":"27","author":"Kong","year":"2018","journal-title":"EBioMedicine"},{"issue":"4","key":"2026060410081236000_dgag156-B27","first-page":"301","article-title":"Acromegaly determination using discriminant analysis of the three-dimensional facial classification in Taiwanese","volume":"38","author":"Wang","year":"2017","journal-title":"Neuro Endocrinol Lett"},{"issue":"7","key":"2026060410081236000_dgag156-B28","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1210\/jc.2011-0237","article-title":"A novel approach to the detection of acromegaly: accuracy of diagnosis by automatic face classification","volume":"96","author":"Schneider","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060410081236000_dgag156-B29","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2265.2011.04020.x","article-title":"Early diagnosis of acromegaly: computers vs clinicians","volume":"75","author":"Miller","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026060410081236000_dgag156-B30","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3389\/fendo.2018.00722","article-title":"3D facial analysis in acromegaly: gender-specific features and clinical correlations","volume":"9","author":"Guo","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2026060410081236000_dgag156-B31","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1210\/clinem\/dgae689","article-title":"Digital voice analysis as a biomarker of acromegaly","volume":"110","author":"Vouzouneraki","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060410081236000_dgag156-B32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/BF03346578","article-title":"Analysis of voice in patients with untreated active acromegaly","volume":"33","author":"Bogazzi","year":"2010","journal-title":"J Endocrinol Invest"},{"key":"2026060410081236000_dgag156-B33","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1109\/ACCESS.2020.3046878","article-title":"Automatic detection for acromegaly using hand photographs: a deep-learning approach","volume":"9","author":"Duan","year":"2021","journal-title":"IEEE Access"},{"issue":"4","key":"2026060410081236000_dgag156-B34","article-title":"Acromegaly type 1: a representative patient","volume":"2","author":"Cuevas-Ramos","year":"2024","journal-title":"JCEM Case Rep"},{"issue":"11","key":"2026060410081236000_dgag156-B35","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","article-title":"Consensus on acromegaly therapeutic outcomes: an update","volume":"21","author":"Melmed","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"2026060410081236000_dgag156-B36","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1210\/jcem.80.12.8530606","article-title":"Sandostatin LAR in acromegalic patients: a dose-range study","volume":"80","author":"Fl\u00f8gstad","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026060410081236000_dgag156-B37","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.metabol.2005.04.014","article-title":"Pharmacokinetics and population pharmacodynamic analysis of lanreotide autogel","volume":"54","author":"Cendros","year":"2005","journal-title":"Metabolism"},{"issue":"9","key":"2026060410081236000_dgag156-B38","doi-asserted-by":"crossref","first-page":"e3644","DOI":"10.1210\/clinem\/dgac385","article-title":"IGF-I variability over repeated measures in patients with acromegaly under long-acting somatostatin receptor ligands","volume":"107","author":"Maione","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060410081236000_dgag156-B39","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/ejendo\/lvaf200","article-title":"Insulin-like growth factor-I and symptoms of acromegaly according to time since somatostatin receptor ligand injection","volume":"193","author":"Remba-Shapiro","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026060410081236000_dgag156-B40","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1210\/jc.2008-1371","article-title":"The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly","volume":"94","author":"Carmichael","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2026060410081236000_dgag156-B41","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1266339","article-title":"Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly","volume":"14","author":"Clemmons","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2026060410081236000_dgag156-B42","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1210\/clinem\/dgz187","article-title":"Biochemical control in acromegaly with multimodality therapies: outcomes from a pituitary center and changes over time","volume":"105","author":"Ghajar","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060410081236000_dgag156-B43","first-page":"41","article-title":"Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the growth hormone research society and the pituitary society","volume":"26","author":"Lim","year":"2005","journal-title":"Clin Biochem Rev"},{"issue":"1","key":"2026060410081236000_dgag156-B44","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1365-2265.2008.03461.x","article-title":"Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly","volume":"71","author":"Sherlock","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"2026060410081236000_dgag156-B45","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an Endocrine Society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060410081236000_dgag156-B46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1023\/B:PITU.0000011174.79946.10","article-title":"Pitfalls in the biochemical assessment of acromegaly","volume":"6","author":"Freda","year":"2003","journal-title":"Pituitary"},{"issue":"12","key":"2026060410081236000_dgag156-B47","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1530\/EC-20-0361","article-title":"Risk factors and management of pasireotide-associated hyperglycemia in acromegaly","volume":"9","author":"Gadelha","year":"2020","journal-title":"Endocr Connect"},{"issue":"6","key":"2026060410081236000_dgag156-B48","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","article-title":"Managing pasireotide-associated hyperglycemia: a randomized, open-label, phase IV study","volume":"24","author":"Samson","year":"2021","journal-title":"Pituitary"},{"issue":"4","key":"2026060410081236000_dgag156-B49","doi-asserted-by":"crossref","first-page":"e1050","DOI":"10.1210\/clinem\/dgaf579","article-title":"Rapid and sustained response of biochemically uncontrolled acromegaly to once-daily oral paltusotine treatment","volume":"111","author":"Biller","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060410081236000_dgag156-B50","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/17446651.2024.2363540","article-title":"Oral octreotide capsules for acromegaly treatment: application of clinical trial insights to real-world use","volume":"19","author":"Fleseriu","year":"2024","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"4","key":"2026060410081236000_dgag156-B51","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2024.101888","article-title":"Treatment of acromegaly with oral octreotide","volume":"38","author":"Remba-Shapiro","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"2026060410081236000_dgag156-B52","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1530\/EJE-22-0220","article-title":"Durable biochemical response and safety with oral octreotide capsules in acromegaly","volume":"187","author":"Samson","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2026060410081236000_dgag156-B53","doi-asserted-by":"crossref","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026060410081236000_dgag156-B54","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2026060410081236000_dgag156-B55","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J Clin Invest"},{"issue":"3","key":"2026060410081236000_dgag156-B56","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11102-011-0310-7","article-title":"Clinical, quality of life, and economic value of acromegaly disease control","volume":"14","author":"Ben-Shlomo","year":"2011","journal-title":"Pituitary"},{"issue":"1","key":"2026060410081236000_dgag156-B57","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"2026060410081236000_dgag156-B58","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026060410081236000_dgag156-B59","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11102-019-01013-2","article-title":"Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider","volume":"23","author":"Geer","year":"2020","journal-title":"Pituitary"},{"issue":"3","key":"2026060410081236000_dgag156-B60","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1530\/EJE-21-1071","article-title":"Virtual education programming for patients with acromegaly: a pilot study","volume":"186","author":"Geer","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026060410081236000_dgag156-B61","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2265.2005.02307.x","article-title":"Assessment of quality of life in patients with uncontrolled vs controlled acromegaly using the acromegaly quality of life questionnaire (AcroQoL)","volume":"63","author":"Trepp","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2026060410081236000_dgag156-B62","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1210\/clinem\/dgab874","article-title":"State of the art of patient-reported outcomes in acromegaly or GH deficiency: a systematic review and meta-analysis","volume":"107","author":"van der Meulen","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060410081236000_dgag156-B63","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s41687-023-00541-7","article-title":"Development and evaluation of the acromegaly symptom diary","volume":"7","author":"Martin","year":"2023","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"2026060410081236000_dgag156-B64","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1210\/clinem\/dgae385","article-title":"Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine","volume":"110","author":"Gadelha","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026060410081236000_dgag156-B65","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1210\/jc.2009-2815","article-title":"Female gonadal function before and after treatment of acromegaly","volume":"95","author":"Grynberg","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060410081236000_dgag156-B66","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12020-018-1540-5","article-title":"Female gonadal functions and ovarian reserve in patients with acromegaly: experience from a single tertiary center","volume":"60","author":"Dogansen","year":"2018","journal-title":"Endocrine"},{"issue":"1","key":"2026060410081236000_dgag156-B67","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12958-024-01207-9","article-title":"Pregnancy and acromegaly: clinical outcomes of retrospectively analysed data from the German acromegaly registry","volume":"22","author":"T\u00f6njes","year":"2024","journal-title":"Reprod Biol Endocrinol"},{"issue":"3","key":"2026060410081236000_dgag156-B68","first-page":"727","article-title":"Pregnancy in acromegaly: successful therapeutic outcome","volume":"83","author":"Herman-Bonert","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026060410081236000_dgag156-B69","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1210\/jc.2009-2331","article-title":"Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women","volume":"95","author":"Caron","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060410081236000_dgag156-B70","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1530\/EJE-13-0460","article-title":"Acromegaly and pregnancy: a prospective study","volume":"170","author":"Dias","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026060410081236000_dgag156-B71","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1530\/eje.1.02215","article-title":"Pregnancy in acromegaly: a one-center experience","volume":"155","author":"Cozzi","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026060410081236000_dgag156-B72","first-page":"223","article-title":"Insulin-like growth factor 1 and its binding protein 1 during normal and diabetic pregnancies","volume":"76","author":"Whittaker","year":"1990","journal-title":"Obstet Gynecol"},{"issue":"2","key":"2026060410081236000_dgag156-B73","first-page":"99","article-title":"Longitudinal study of the maternal insulin-like growth factor system before, during and after pregnancy in relation to fetal and infant weight","volume":"69","author":"Olausson","year":"2008","journal-title":"Horm Res"},{"issue":"2","key":"2026060410081236000_dgag156-B74","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1507\/endocrj.53.209","article-title":"Normal delivery following an uneventful pregnancy in a Japanese acromegalic patient after discontinuation of octreotide long acting release formulation at an early phase of pregnancy","volume":"53","author":"Takano","year":"2006","journal-title":"Endocr J"},{"issue":"4","key":"2026060410081236000_dgag156-B75","doi-asserted-by":"crossref","first-page":"K21","DOI":"10.1530\/EJE-18-0688","article-title":"Pregnancy in acromegaly is safe and is associated with improvements in IGF-1 concentrations","volume":"180","author":"Hannon","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2026060410081236000_dgag156-B76","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000147167","article-title":"Does the physiological acromegaly of pregnancy benefit the fetus?","volume":"66","author":"Verhaeghe","year":"2008","journal-title":"Gynecol Obstet Invest"},{"issue":"5","key":"2026060410081236000_dgag156-B77","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1210\/er.2003-0035","article-title":"Estrogen regulation of growth hormone action","volume":"25","author":"Leung","year":"2004","journal-title":"Endocr Rev"},{"issue":"11","key":"2026060410081236000_dgag156-B78","first-page":"3771","article-title":"Expression of somatostatin receptor SST4 in human placenta and absence of octreotide effect on human placental growth hormone concentration during pregnancy","volume":"82","author":"Caron","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060410081236000_dgag156-B79","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12902-023-01341-2","article-title":"Safety of pregnancy in acromegaly patients and maternal and infant outcomes after pregnancy: single-center experience from China and review of the literature","volume":"23","author":"Jiao","year":"2023","journal-title":"BMC Endocr Disord"},{"key":"2026060410081236000_dgag156-B80","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2021.101417","article-title":"Course and outcomes of pregnancy in women treated for acromegaly: discerning a contemporary cohort","volume":"60-61","author":"Das","year":"2021","journal-title":"Growth Horm IGF Res"},{"issue":"5","key":"2026060410081236000_dgag156-B81","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s11102-020-01050-2","article-title":"Preconception use of pegvisomant alone or as combination therapy for acromegaly: a case series and review of the literature","volume":"23","author":"Guarda","year":"2020","journal-title":"Pituitary"},{"issue":"6","key":"2026060410081236000_dgag156-B82","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/cen.13599","article-title":"Outcome of pregnancies in a large cohort of women with acromegaly","volume":"88","author":"Jallad","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026060410081236000_dgag156-B83","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s12020-014-0508-3","article-title":"Pregnancy in acromegaly patients treated with pegvisomant","volume":"49","author":"van der Lely","year":"2015","journal-title":"Endocrine"},{"issue":"3","key":"2026060410081236000_dgag156-B84","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/s-2005-873004","article-title":"Follow-up of pregnancy in acromegalic women: different presentations and outcomes","volume":"114","author":"Atmaca","year":"2006","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"2026060410081236000_dgag156-B85","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1046\/j.1365-2265.2001.01304.x","article-title":"Octreotide LAR treatment throughout pregnancy in an acromegalic woman","volume":"55","author":"Fassnacht","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"2026060410081236000_dgag156-B86","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJM199508313330918","article-title":"Maternal-fetal transfer of octreotide","volume":"333","author":"Caron","year":"1995","journal-title":"N Engl J Med"},{"issue":"5 Pt 2","key":"2026060410081236000_dgag156-B87","first-page":"848","article-title":"Successful pregnancy in an acromegalic women treated with octreotide","volume":"93","author":"Takeuchi","year":"1999","journal-title":"Obstet Gynecol"},{"issue":"3","key":"2026060410081236000_dgag156-B88","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4065\/77.3.297-a","article-title":"Octreotide treatment of acromegaly during pregnancy","volume":"77","author":"Mikhail","year":"2002","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"2026060410081236000_dgag156-B89","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2265.2009.03706.x","article-title":"Effects of octreotide exposure during pregnancy in acromegaly","volume":"72","author":"Maffei","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"2026060410081236000_dgag156-B90","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1210\/jc.2007-0997","article-title":"Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects","volume":"92","author":"Brian","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026060410081236000_dgag156-B91","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.3390\/diagnostics12112669","article-title":"Approach of acromegaly during pregnancy","volume":"12","author":"Popescu","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"9","key":"2026060410081236000_dgag156-B92","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1210\/jcem.82.9.4257","article-title":"Acromegaly","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2026060410081236000_dgag156-B93","first-page":"433","article-title":"Safe treatment with somatostatin analogues in a woman with acromegaly whilst pregnant and lactating","volume":"42","author":"Babinska","year":"2021","journal-title":"Neuro Endocrinol Lett"},{"issue":"1","key":"2026060410081236000_dgag156-B94","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/1753495X15598699","article-title":"Preconception counselling for women with acromegaly: more questions than answers","volume":"9","author":"Assal","year":"2016","journal-title":"Obstet Med"},{"issue":"1","key":"2026060410081236000_dgag156-B95","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/17446651.2024.2448784","article-title":"Acromegaly: diagnostic challenges and individualized treatment","volume":"20","author":"Freda","year":"2025","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"11","key":"2026060410081236000_dgag156-B96","doi-asserted-by":"crossref","first-page":"6290","DOI":"10.1210\/jc.2005-0998","article-title":"The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly","volume":"90","author":"Bhayana","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060410081236000_dgag156-B97","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12020-014-0383-y","article-title":"Growth hormone tumor histological subtypes predict response to surgical and medical therapy","volume":"49","author":"Kiseljak-Vassiliades","year":"2015","journal-title":"Endocrine"},{"issue":"9","key":"2026060410081236000_dgag156-B98","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1210\/clinem\/dgaa387","article-title":"Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly","volume":"105","author":"Coopmans","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2026060410081236000_dgag156-B99","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.677919","article-title":"Clinical and radiological predictors of biochemical response to first-line treatment with somatostatin receptor ligands in acromegaly: a real-life perspective","volume":"12","author":"Nista","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026060410081236000_dgag156-B100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2022.101502","article-title":"Age, GH\/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: a clinicopathological study","volume":"67","author":"Durmu\u015f","year":"2022","journal-title":"Growth Horm IGF Res"},{"issue":"1","key":"2026060410081236000_dgag156-B101","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/jcm12010025","article-title":"Resistance to somatostatin analogs in Italian acromegaly patients: the MISS study","volume":"12","author":"Berton","year":"2022","journal-title":"J Clin Med"},{"issue":"4","key":"2026060410081236000_dgag156-B102","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience","volume":"16","author":"Brzana","year":"2013","journal-title":"Pituitary"},{"issue":"2","key":"2026060410081236000_dgag156-B103","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-13-0349","article-title":"Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern","volume":"169","author":"Kasuki","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2026060410081236000_dgag156-B104","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1210\/clinem\/dgac512","article-title":"Predictive factors of somatostatin receptor ligand response in acromegaly\u2013a prospective study","volume":"107","author":"Ilie","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026060410081236000_dgag156-B105","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.957301","article-title":"Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly","volume":"13","author":"Tomasik","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"2026060410081236000_dgag156-B106","doi-asserted-by":"crossref","DOI":"10.1530\/EC-25-0103","article-title":"Predictors of therapeutic failure in GH and prolactin co-secreting pituitary adenomas","volume":"14","author":"Araujo-Castro","year":"2025","journal-title":"Endocr Connect"},{"issue":"6","key":"2026060410081236000_dgag156-B107","doi-asserted-by":"crossref","DOI":"10.4329\/wjr.v17.i6.106438","article-title":"Factors affecting disease control after pituitary tumor resection in acromegaly: what is the current evidence?","volume":"17","author":"Fernandez","year":"2025","journal-title":"World J Radiol"},{"issue":"3","key":"2026060410081236000_dgag156-B108","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-07-0562","article-title":"Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR","volume":"158","author":"Taboada","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2026060410081236000_dgag156-B109","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1530\/ERC-18-0565","article-title":"Molecular profiling for acromegaly treatment: a validation study","volume":"27","author":"Puig-Domingo","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2026060410081236000_dgag156-B110","doi-asserted-by":"crossref","first-page":"L25","DOI":"10.1530\/ERC-12-0020","article-title":"AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression","volume":"19","author":"Kasuki","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"2026060410081236000_dgag156-B111","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1530\/EJE-15-0391","article-title":"Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly","volume":"174","author":"Gatto","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026060410081236000_dgag156-B112","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1111\/jcmm.13851","article-title":"E-cadherin expression is associated with somatostatin analogue response in acromegaly","volume":"23","author":"Venegas-Moreno","year":"2019","journal-title":"J Cell Mol Med"},{"issue":"5","key":"2026060410081236000_dgag156-B113","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/cen.14339","article-title":"Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GH-producing adenomas","volume":"94","author":"Gil","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2026060410081236000_dgag156-B114","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1210\/clinem\/dgaf375","article-title":"Integrative machine learning approach for predicting resistance to first-generation receptor ligands in acromegaly","volume":"111","author":"Lin","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060410081236000_dgag156-B115","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1210\/clinem\/dgae444","article-title":"Personalized medicine in acromegaly: the ACROFAST study","volume":"110","author":"Marques-Pamies","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026060410081236000_dgag156-B116","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060410081236000_dgag156-B117","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2024.101893","article-title":"Predictors of biochemical response to somatostatin receptor ligands in acromegaly","volume":"38","author":"Marazuela","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"16","key":"2026060410081236000_dgag156-B118","doi-asserted-by":"crossref","first-page":"8663","DOI":"10.3390\/ijms25168663","article-title":"Predicting response to medical treatment in acromegaly via granulation pattern, expression of somatostatin receptors type 2 and 5 and E-Cadherin","volume":"25","author":"Gliga","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2026060410081236000_dgag156-B119","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.3390\/ijms24032875","article-title":"miR-383-5p, miR-181a-5p, and miR-181b-5p as predictors of response to first-generation somatostatin receptor ligands in acromegaly","volume":"24","author":"Henriques","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026060410081236000_dgag156-B120","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ebiom.2019.04.007","article-title":"Unmasking a new prognostic marker and therapeutic target from the GDNF-RET\/PIT1\/p14ARF\/p53 pathway in acromegaly","volume":"43","author":"Chenlo","year":"2019","journal-title":"EBioMedicine"},{"issue":"6","key":"2026060410081236000_dgag156-B121","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1210\/clinem\/dgae707","article-title":"Octreotide subcutaneous depot for acromegaly: a randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1","volume":"110","author":"Ferone","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026060410081236000_dgag156-B122","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2265.2004.02084.x","article-title":"Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly","volume":"61","author":"Turner","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026060410081236000_dgag156-B123","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2265.2003.01710.x","article-title":"Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval","volume":"58","author":"Biermasz","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2026060410081236000_dgag156-B124","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1055\/s-0030-1267244","article-title":"Efficacy and acceptability of lanreotide Autogel\u00ae 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR","volume":"119","author":"Schopohl","year":"2011","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"2026060410081236000_dgag156-B125","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1530\/EJE-15-0215","article-title":"Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study","volume":"173","author":"Neggers","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2026060410081236000_dgag156-B126","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11102-022-01285-1","article-title":"A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly","volume":"26","author":"Fleseriu","year":"2023","journal-title":"Pituitary"},{"issue":"3","key":"2026060410081236000_dgag156-B127","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s12020-020-02424-z","article-title":"Effectiveness of lanreotide Autogel 120 mg at extended dosing intervals for acromegaly","volume":"70","author":"Bernab\u00e9u","year":"2020","journal-title":"Endocrine"},{"issue":"10","key":"2026060410081236000_dgag156-B128","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0155","article-title":"Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly","volume":"12","author":"Marques","year":"2023","journal-title":"Endocr Connect"},{"issue":"9","key":"2026060410081236000_dgag156-B129","doi-asserted-by":"crossref","first-page":"-","DOI":"10.1210\/clinem\/dgaa444","article-title":"Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial","volume":"105","author":"Bonert","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026060410081236000_dgag156-B130","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1530\/EJE-08-0990","article-title":"Successful use of weekly pegvisomant administration in patients with acromegaly","volume":"161","author":"Higham","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026060410081236000_dgag156-B131","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11102-010-0289-5","article-title":"Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients","volume":"14","author":"Neggers","year":"2011","journal-title":"Pituitary"},{"issue":"5","key":"2026060410081236000_dgag156-B132","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1530\/EJE-07-0383","article-title":"Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly","volume":"157","author":"Colao","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2026060410081236000_dgag156-B133","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2017-00142","article-title":"High-dose and high-frequency lanreotide Autogel in acromegaly: a randomized, multicenter study","volume":"102","author":"Giustina","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026060410081236000_dgag156-B134","doi-asserted-by":"crossref","first-page":"305","DOI":"10.5603\/EP.a2019.0023","article-title":"Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study","volume":"70","author":"Colao","year":"2019","journal-title":"Endokrynol Pol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag156\/68081365\/dgag156.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/Supplement_1\/S107\/68081365\/dgag156.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/Supplement_1\/S107\/68081365\/dgag156.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:08:32Z","timestamp":1780582112000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/Supplement_1\/S107\/8654123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":134,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2026,4,15]]},"published-print":{"date-parts":[[2026,6,4]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag156","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,4,15]]}}}